Lyttelton M P, Newlands E S, Giles C, Bower M, Guimaraes A, O'Reilly S, Rustin G J, Samson D, Kanfer E J
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospitals NHS Trust, London, UK.
Br J Cancer. 1998 May;77(10):1672-6. doi: 10.1038/bjc.1998.275.
Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.
31例复发或难治性生殖细胞肿瘤(GCT)患者接受了含卡铂的高剂量化疗(HDT)方案,卡铂剂量根据测得的肾小球滤过率进行调整。发生1例HDT相关死亡(3%),死因是急性肾衰竭。21例原发性难治性疾病或反应性复发患者的3年总生存率和无病生存率分别为60%和42%,而10例难治性复发患者均无病生存。